Moleculin to Present at Two Upcoming Investor Conferences
Moleculin Biotech, Inc. (Nasdaq: MBRX), a late-stage pharmaceutical company focusing on hard-to-treat tumors and viruses, has announced its participation in two upcoming investor conferences. The first is the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024, where Moleculin will participate in a panel discussion on Innovative Therapies for Liquid Tumors at 1:15 PM ET. The panel will cover drug developments, competitive positioning, and upcoming data readouts.
The second event is the 2024 Healthcare Virtual Summit, presented by Maxim Group and hosted by M-Vest, scheduled for October 16, 2024, at 3:00 PM ET. Moleculin will participate in a fireside chat format. This virtual event will be accessible to M-Vest members, with registration available online. Both conferences offer opportunities for Moleculin to showcase its drug candidates and engage with the investor community.
Moleculin Biotech, Inc. (Nasdaq: MBRX), una società farmaceutica in fase avanzata che si concentra su tumori e virus difficili da trattare, ha annunciato la sua partecipazione a due prossime conferenze per investitori. La prima è la 3ª Conferenza Annuale sulle Opportunità Sanitarie ROTH che si terrà il 9 ottobre 2024, dove Moleculin parteciperà a una discussione in panel sulle Terapie Innovative per Tumori Liquidi alle 13:15 ET. Il panel tratterà degli sviluppi dei farmaci, della posizione competitiva e delle prossime letture di dati.
Il secondo evento è il Summit Virtuale Sanitario 2024, presentato da Maxim Group e ospitato da M-Vest, previsto per il 16 ottobre 2024, alle 15:00 ET. Moleculin parteciperà in formato di chat accogliente. Questo evento virtuale sarà accessibile ai membri di M-Vest, con registrazione disponibile online. Entrambe le conferenze offrono opportunità a Moleculin per mostrare i suoi candidati farmaci e interagire con la comunità degli investitori.
Moleculin Biotech, Inc. (Nasdaq: MBRX), una compañía farmacéutica en etapa avanzada que se enfoca en tumores y virus difíciles de tratar, ha anunciado su participación en dos próximas conferencias para inversionistas. La primera es la 3ª Conferencia Anual de Oportunidades en Salud ROTH, que se llevará a cabo el 9 de octubre de 2024, donde Moleculin participará en una discusión de panel sobre Terapiás Innovadoras para Tumores Líquidos a la 1:15 PM ET. El panel cubrirá el desarrollo de medicamentos, la posición competitiva y las próximas lecturas de datos.
El segundo evento es el Summit Virtual de Salud 2024, presentado por Maxim Group y organizado por M-Vest, programado para el 16 de octubre de 2024, a las 3:00 PM ET. Moleculin participará en un formato de charla informal. Este evento virtual será accesible para los miembros de M-Vest, con registro disponible en línea. Ambas conferencias ofrecen oportunidades para que Moleculin muestre sus candidatos a fármacos y se involucre con la comunidad inversora.
몰레큘린 바이오텍, Inc. (Nasdaq: MBRX), 난치성 종양 및 바이러스에 초점을 맞춘 후기 단계의 제약 회사는 두 개의 다가오는 투자자 회의에 참여한다고 발표했습니다. 첫 번째 회의는 2024년 10월 9일에 열리는 제3회 연례 ROTH 헬스케어 기회 회의로, 몰레큘린은 액체 종양에 대한 혁신적 치료법에 대한 패널 토론에 1:15 PM ET에 참여합니다. 본 패널은 약물 개발, 경쟁 위치 및 향후 데이터 발표에 대해 다룰 것입니다.
두 번째 이벤트는 Maxim Group이 주최하고 M-Vest가 주관하는 2024 헬스케어 가상 서밋으로, 2024년 10월 16일 오후 3시 ET에 예정되어 있습니다. 몰레큘린은 편안한 대화 형식으로 참여합니다. 이 가상 이벤트는 M-Vest 회원에게 접근 가능하며, 온라인으로 등록할 수 있습니다. 두 회의 모두 몰레큘린이 자사의 약물 후보를 선보이고 투자자 커뮤니티와 소통할 수 있는 기회를 제공합니다.
Moleculin Biotech, Inc. (Nasdaq: MBRX), une société pharmaceutique en phase avancée spécialisée dans les tumeurs et virus difficiles à traiter, a annoncé sa participation à deux prochaines conférences pour investisseurs. La première est la 3e Conférence Annuelle sur les Opportunités de Santé ROTH, qui aura lieu le 9 octobre 2024, pendant laquelle Moleculin participera à un débat sur Thérapies Innovantes pour Tumors Liquides à 13h15 ET. Le panel abordera le développement des médicaments, la position concurrentielle et les prochaines publications de données.
Le deuxième événement est le Sommet Virtuel sur la Santé 2024, présenté par Maxim Group et animé par M-Vest, prévu pour le 16 octobre 2024 à 15h00 ET. Moleculin participera sous la forme d'une discussion informelle. Cet événement virtuel sera accessible aux membres de M-Vest, avec une inscription disponible en ligne. Les deux conférences offrent à Moleculin l'opportunité de présenter ses candidats-médicaments et d'engager la communauté des investisseurs.
Moleculin Biotech, Inc. (Nasdaq: MBRX), ein biopharmazeutisches Unternehmen in der späten Phase, das sich auf schwer zu behandelnde Tumoren und Viren konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Die erste ist die 3. Jahreskonferenz über Gesundheitsmöglichkeiten von ROTH, die am 9. Oktober 2024 stattfinden wird, wo Moleculin an einer Podiumsdiskussion über Innovative Therapien für Flüssigtumoren um 13:15 Uhr ET teilnehmen wird. Das Panel wird die Arzneimittelentwicklung, die Wettbewerbspositionierung und bevorstehende Datenberichterstattungen behandeln.
Die zweite Veranstaltung ist der Virtuelle Gesundheitsgipfel 2024, der von der Maxim Group präsentiert und von M-Vest ausgerichtet wird, und der für den 16. Oktober 2024 um 15:00 Uhr ET geplant ist. Moleculin wird an einem „Fireside Chat“-Format teilnehmen. Diese virtuelle Veranstaltung wird für M-Vest-Mitglieder zugänglich sein und eine Online-Registrierung wird verfügbar sein. Beide Konferenzen bieten Moleculin die Möglichkeit, seine Arzneimittelkandidaten zu präsentieren und mit der Investorenbeziehung zu interagieren.
- None.
- None.
Details of the upcoming presentations are as follows:
3rd Annual ROTH Healthcare Opportunities Conference
- Format: Panel - Innovative Therapies for Liquid Tumors
- The panel will cover the drugs in development by the presenting companies and where they fit competitively for the initial indication as well as for potential subsequent indications, and upcoming data readouts.
- Date: Wednesday, October 9, 2024
- Time: 1:15 – 1:55 PM ET
Panel presentations will be accessible by those registered to attend the conference. In addition to the panel presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the event.
2024 Healthcare Virtual Summit, Presented by Maxim Group and hosted by M-Vest
- Format: Fireside chat
- Date: Wednesday, October 16, 2024
- Time: 3:00 PM ET
This conference will be live on M-Vest. To attend, just sign up to become an M-Vest member. Click Here to Reserve Your Seat.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.
For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-to-present-at-two-upcoming-investor-conferences-302267367.html
SOURCE Moleculin Biotech, Inc.
FAQ
When is Moleculin Biotech (MBRX) presenting at the ROTH Healthcare Opportunities Conference?
What is the format of Moleculin's (MBRX) presentation at the ROTH conference?
When and where is Moleculin (MBRX) participating in the 2024 Healthcare Virtual Summit?
How can investors attend Moleculin's (MBRX) presentation at the Healthcare Virtual Summit?
